# AgomAb Therapeutics - Full Context for AI Agents

> This file provides comprehensive context about AgomAb Therapeutics for AI agents.
> Source: TechWiki.ai - The Belgian Tech Encyclopedia
> Last updated: 2026-04-07

## Company Profile
- Name: AgomAb Therapeutics
- Sector: biotech
- Stage: public
- Status: active
- Total funding: $300M+
- Location: Ghent, Flanders, Belgium
- Founders: Tim Knotnerus

## Overview
AgomAb Therapeutics was spun out of argenx (https://techwiki.ai/companies/argenx/llms.txt), Ghent (https://techwiki.ai/cities/ghent/llms.txt)'s globally recognized antibody platform company. AgomAb focuses on fibrosis, a condition where scar tissue builds up in organs and progressively impairs their function. There are limited treatment options for fibrosis across its multiple organ manifestations, making it a high-value target for drug development.

The $100M Series C in 2023 is a significant raise that positions AgomAb to advance its pipeline through clinical stages. The argenx (https://techwiki.ai/companies/argenx/llms.txt) lineage provides both scientific credibility and a network of relationships with global pharma partners.

AgomAb is part of the Ghent (https://techwiki.ai/cities/ghent/llms.txt) life sciences cluster, which includes argenx (https://techwiki.ai/companies/argenx/llms.txt) and a growing number of biotech spin-offs benefiting from proximity to Ghent University (https://techwiki.ai/hubs/ugent/llms.txt) research.

## Funding History
- Series C: $100M (2023)
- IPO on Nasdaq: $200M raised (February 2026), $16/share, valuation approximately $780M, ticker AGMB. Underwriters: JP Morgan, Morgan Stanley. See AgomAb Therapeutics IPO 2026 (https://techwiki.ai/deals/agomab-ipo-2026/llms.txt).

## Related Pages
Agents can crawl these for connected context:
- [city] Ghent: https://techwiki.ai/cities/ghent/llms.txt
- [company] argenx: https://techwiki.ai/companies/argenx/llms.txt
- [hub] Ghent University: https://techwiki.ai/hubs/ugent/llms.txt
- [deal] AgomAb Therapeutics IPO 2026: https://techwiki.ai/deals/agomab-ipo-2026/llms.txt
- [person] Tim Knotnerus: https://techwiki.ai/people/tim-knotnerus/llms.txt
- [sector] BioTech & Life Sciences: https://techwiki.ai/sectors/biotech/llms.txt

## Recent News
- [2026-04-24] Belgisch biotechbedrijf Agomab heeft cash tot half 2029 (https://www.tijd.be/r/t/1/id/10657922)

## Links
- Agent context: https://techwiki.ai/companies/agomab-therapeutics/llms.txt
- Full context: https://techwiki.ai/companies/agomab-therapeutics/llms-full.txt

---
Generated by TechWiki.ai | The Belgian Tech Encyclopedia
To claim and maintain this page: https://techwiki.ai/claim